Sanofi (SNYNF) PEG Ratio

N/A

PE ratio relative to earnings growth — is the valuation justified?

—

PEG Ratio

Negative EPS growth — PEG not meaningful when earnings are declining

—

Growth Rate Source

Good Data Quality5-Year EPS CAGR

Current Price

$93.77

TTM EPS

$8.46

P/E Ratio

11.08

Growth Rate

-8.2%

5-Year EPS CAGR

Sector

Healthcare

Drug Manufacturers - General

Calculated

7/28/2026

7:30:24 PM

PEG Ratio Unavailable

Negative Growth — PEG not meaningful

Peer Comparison

Sample Size

7 peers

Industry Median PEG

1.53

25th Percentile

0.21

75th Percentile

3.37

Symbol	Company	PEG	P/E	Growth	vs SNYNF
GILD	Gilead Sciences, Inc.	0.12	17.8	149.5%	—
AZN	AstraZeneca PLC	0.21	12.7	61.0%	—
GSK	GSK plc	0.99	14.3	14.4%	—
NVS	Novartis AG	1.53	23.5	15.4%	—
MRK	Merck & Co., Inc.	1.74	36.8	21.2%	—

How to Interpret PEG Ratio

PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.

PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."

PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.

Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.

Sanofi (SNYNF) PEG Ratio

Peer Comparison

How to Interpret PEG Ratio

More on SNYNF

Compare with peers

Explore

Sanofi (SNYNF) PEG Ratio

Peer Comparison

How to Interpret PEG Ratio

More on SNYNF

Compare with peers

Explore